BRIEF published on 06/21/2024 at 18:35, 2 years ago Formulaire 8.3 - Lupus alpha Asset Management AG : Crest Nicholson Holdings Plc Titres Divulgation Code De Reprise Crête Nicholson Lupus Alpha
BRIEF published on 06/21/2024 at 18:35, 2 years ago Form 8.3 - Lupus alpha Asset Management AG: Crest Nicholson Holdings Plc Securities Disclosure Takeover Code Crest Nicholson Lupus Alpha
PRESS RELEASE published on 06/21/2024 at 18:30, 2 years ago Form 8.3 - Lupus alpha Asset Management AG: Crest Nicholson Holdings Plc Lupus alpha Asset Management AG discloses a 2.49% interest in Crest Nicholson Holdings Plc. Public disclosure under Rule 8.3 of the Takeover Code Disclosure Rule 8.3 Takeover Code Crest Nicholson Holdings Plc Lupus Alpha Asset Management AG
PRESS RELEASE published on 06/21/2024 at 18:30, 2 years ago Form 8.3 - Lupus alpha Asset Management AG: Crest Nicholson Holdings Plc Lupus alpha Asset Management AG discloses a 2.78% stake in Crest Nicholson Holdings Plc. The disclosure was made on 17.06.2024 according to Form 8.3 under the Takeover Code Form 8.3 Takeover Code Stake Disclosure Crest Nicholson Holdings Plc Lupus Alpha Asset Management AG
PRESS RELEASE published on 06/21/2024 at 18:30, 2 years ago Form 8.3 - Lupus alpha Asset Management AG: Crest Nicholson Holdings Plc Lupus alpha Asset Management AG discloses 2.83% stake in Crest Nicholson Holdings Plc. Details of the position disclosed as per Form 8.3 Securities Form 8.3 Disclosure Crest Nicholson Holdings Plc Lupus Alpha Asset Management AG
PRESS RELEASE published on 06/21/2024 at 18:30, 2 years ago Form 8.3 - Lupus alpha Asset Management AG: Crest Nicholson Holdings Plc Lupus alpha Asset Management AG discloses 2.89% stake in Crest Nicholson Holdings Plc as of 19.06.2024 per Form 8.3 disclosure Securities Form 8.3 Disclosure Crest Nicholson Holdings Plc Lupus Alpha Asset Management AG
PRESS RELEASE published on 10/16/2023 at 10:30, 2 years 8 months ago Form 8.3 - Lupus alpha Asset Management AG: The Restaurant Group plc
PRESS RELEASE published on 10/13/2023 at 14:15, 2 years 8 months ago Form 8.3 - Lupus alpha Asset Management AG: The Restaurant Group plc
Published on 06/26/2026 at 14:05, 2 hours 18 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 2 hours 23 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 3 hours 23 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 3 hours 38 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 53 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 59 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 1 minute ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 07:00, 9 hours 23 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 9 hours 23 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
